For instance, XEN496 which is currently in a phase III trial, targets the potassium voltage-gated channel subfamily Q member 2 developmental and epileptic encephalopathy (KCNQ2-DEE), a specific epilepsy syndrome [233]. This evidence concerns the gene KCNQ2 and epilepsy syndrome.